Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment.

ABSTRACT:

Background/aims

Disease-modifying therapy for Alzheimer's disease (AD) has led to a need for biomarkers to identify prodromal AD and very early stage of AD dementia. We aimed to identify the cutoff values of cerebrospinal fluid (CSF) biomarkers for detecting prodromal AD.

Methods

We assessed 56 patients with amnestic mild cognitive impairment (aMCI) who underwent lumbar puncture. Additionally, 87 healthy elderly individuals and 34 patients with AD dementia served as controls. Positron emission tomography was performed using florbetaben as a probe. We analyzed the concentration of Aβ_1-42, total tau protein (t-Tau), and tau protein phosphorylated at threonine 181 (p-Tau¹⁸¹) in CSF with INNOTEST enzyme-linked immunosorbent assay.

Results

For the det

SUBMITTER: Park JE 

PROVIDER: S-EPMC6465729 | biostudies-literature | 2019 Jan-Apr

REPOSITORIES: biostudies-literature